Bortezomib is a first-generation proteasome inhibitor which was approved for its medical use on 13th May 2003.

Bortezomib has been developed to treat adult patients diagnosed with Multiple myeloma and mantle cell lymphoma.

Bortezomib is available in the form of single dose vial containing lyophilized powder for injection in the doses 1mg, 2mg, 2.5mg, 3.5mg. Bortezomib Injection is intended for administration through intravenous and subcutaneous route only. Your healthcare provider will calculate the accurate dose depending on your health condition and the route of administration.

The common side effects that are likely to occur while you are on the treatment with Bortezomib are diarrhoea, rash, nausea, thrombocytopenia, neutropenia, tiredness, fever, vomiting, constipation, loss of appetite, etc. Serious side effects include heart problems, dizziness, confusion, tumor lysis syndrome, peripheral neuropathy, respiratory problems, liver problems, low blood cell counts. If you experience any allergic reactions such as swelling of lips, eyes, face, or tongue, hives, skin rashes, breathing trouble, report to your doctor immediately.

Contact your doctor immediately if you experience increase in blood pressure, bleeding, fever or constipation. During the Bortezomib treatment, your doctor may periodically monitor your blood cell counts, platelets, blood sugar, electrolytes, liver and kidney parameters to prevent serious complications. Report to your doctor if you have been diagnosed with anaemia, liver problems, kidney disease, heart problem, etc. Get immediate medical attention if you experience itchy skin, rashes, or signs of infection or bleeding.

Bortezomib can cause potential risk to the foetus. Hence it is advisable to use an effective contraception during treatment with bortezomib and for 7 months following the last dose. male patients with female partners of reproductive potential should use an effective contraceptive during treatment with bortezomib and for four months following the last dose. Report to your healthcare provider immediately if you or your female partner become pregnant during treatment or within 7 months after the last dose. It is not recommended to breastfeed during treatment with bortezomib and for two months after the last dose.

Bortezomib can cause dizziness, postural hypotension and confusion. Therefore, it is advisable to avoid driving or doing activities that require your focus during this treatment. Drink sufficient fluids to avoid dehydration. Your blood sugar level frequently If you are taking antidiabetic medication and report your physician if you notice any fluctuations in your blood sugar levels.

1. Takeda Pharmaceuticals U.S.A., Inc., US Food & Drug Administration, [Revised on Aug 2022] [Accessed on 9th Sep 2022], https://www.velcade.com/files/pdfs/VELCADE_PRESCRIBING_INFORMATION.pdf
2. Anton Wellstein, Giuseppe Giaccone, Michael B. Atkins, and Edward A. Sausville, Pathway-Targeted Therapies: Monoclonal Antibodies, Protein Kinase Inhibitors, and Various Small Molecules, Goodman & Gilman’s Pharmacological Basis of Therapeutics, 13th Edition, 2018, 1203-1236.

The drug information on this page is not a substitute for medical advice, it is meant for educational purposes only. For further details consult your doctor about your medical condition to know if you are eligible to receive this treatment.